Literature DB >> 24121269

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.

P Basova1, V Pospisil2, F Savvulidi2, P Burda2, K Vargova2, L Stanek3, M Dluhosova2, E Kuzmova2, A Jonasova4, U Steidl5, P Laslo6, T Stopka4.   

Abstract

PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1(ure/ure) mice (PU.1(ure/ure)p53(-/-)) results in more aggressive AML with shortened overall survival. PU.1(ure/ure)p53(-/-) progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1(ure/ure)p53(-/-) mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24121269     DOI: 10.1038/onc.2013.414

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.

Authors:  Petra Bašová; Helena Paszeková; Lubomír Minařík; Martina Dluhošová; Pavel Burda; Tomáš Stopka
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

2.  Acute myeloid leukemia with TP53 germ line mutations.

Authors:  Armin Zebisch; Ridhima Lal; Marian Müller; Karin Lind; Karl Kashofer; Michael Girschikofsky; David Fuchs; Albert Wölfler; Jochen B Geigl; Heinz Sill
Journal:  Blood       Date:  2016-09-12       Impact factor: 22.113

Review 3.  PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.

Authors:  Tom Verbiest; Simon Bouffler; Stephen L Nutt; Christophe Badie
Journal:  Carcinogenesis       Date:  2015-03-06       Impact factor: 4.944

4.  GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.

Authors:  Pavel Burda; Jarmila Vargova; Nikola Curik; Cyril Salek; Giorgio Lucio Papadopoulos; John Strouboulis; Tomas Stopka
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

Review 5.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

Review 6.  Overview of the Use of Murine Models in Leukemia and Lymphoma Research.

Authors:  Rebecca Kohnken; Pierluigi Porcu; Anjali Mishra
Journal:  Front Oncol       Date:  2017-02-20       Impact factor: 6.244

Review 7.  MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.

Authors:  Stefania Trino; Daniela Lamorte; Antonella Caivano; Ilaria Laurenzana; Daniela Tagliaferri; Geppino Falco; Luigi Del Vecchio; Pellegrino Musto; Luciana De Luca
Journal:  Int J Mol Sci       Date:  2018-02-03       Impact factor: 5.923

8.  Dynamical Analysis of the Regulatory Network Controlling Natural Killer Cells Differentiation.

Authors:  Adhemar J Liquitaya-Montiel; Luis Mendoza
Journal:  Front Physiol       Date:  2018-08-02       Impact factor: 4.566

9.  Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML.

Authors:  Gráinne O'Brien; Lourdes Cruz-Garcia; Joanna Zyla; Natalie Brown; Rosemary Finnon; Joanna Polanska; Christophe Badie
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

Review 10.  Intricate crosstalk between MYB and noncoding RNAs in cancer.

Authors:  Dingyu Hu; Wenjun Shao; Li Liu; Yanyan Wang; Shunling Yuan; Zhaoping Liu; Jing Liu; Ji Zhang
Journal:  Cancer Cell Int       Date:  2021-12-07       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.